Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AZD1402 Inhalation Device and Formulation in Healthy Subjects
NCT03921268Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2019
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of elarekibep in asthma (3 arms), sponsored by AstraZeneca. Primary endpoints: Area under serum concentration-time curve from zero to infinity, Area under serum concentration-time curve from zero to infinity divided by dose and 10 more. Started Mar 2019; status: completed.
02
Drugs
elarekibep
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03921268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921268.